Pronounce: gloe-fi-TA-mab gxbm
Classification: Targeted Therapy
A targeted therapy works by targeting receptors specific to cancer cells. Glofitamab-gxbm is a CD20-directed CD3 T-cell engager. This medication binds to the CD3 receptor found on the surface of some T-cells and CD20 which is found on some lymphoma cells.
This medication is given as an intravenous (IV, into a vein) infusion. One week before you are given this medication, you will be given a medication called obinutuzumab. Before your dose of glofitamab-gxbm, you will be given pre-medications to prevent a reaction including a steroid (prednisone or dexamethasone), a histamine-1 (H1) receptor antagonist (such as diphenhydramine/Benadryl), and an antipyretic (such as acetaminophen/Tylenol). You may also be given antiviral medications and medications to prevent pneumonia. You will need to be in the hospital while receiving this medication and for at least 24 hours after your dose is done.
There are a number of things you can do to manage the side effects of glofitamab-gxbm. Talk to your care team about these recommendations. They can help you decide what will work best for you. These are some of the most common or important side effects:
CRS can occur. T cells are activated by this medication, causing them to release many cytokines. The cytokines cause an inflammatory response in the body. This reaction, if left untreated, can be very dangerous. Signs and symptoms may be fever, having a hard time breathing, chills, low blood pressure, fast heart rate, headache, and higher levels of liver enzymes in your blood. Your care team will monitor you closely for CRS while you are receiving this medication. You should call your provider right away if you have any signs or symptoms of CRS so that treatment can be started.
This medication can cause life-threatening infections, with or without a decrease in white blood cell counts.
White blood cells (WBC) are important for fighting infection. While receiving treatment, your WBC count can drop, putting you at a higher risk of getting an infection. You should let your doctor or nurse know right away if you have a fever (temperature greater than 100.4 °F or 38°C), sore throat or cold, shortness of breath, cough, burning with urination, or a sore that doesn't heal.
Tips to preventing infection:
Your healthcare provider can recommend medications and other strategies to help relieve pain.
Fatigue is very common during cancer treatment and is an overwhelming feeling of exhaustion that is not usually relieved by rest. While on cancer treatment, and for a period after, you may need to adjust your schedule to manage fatigue. Plan times to rest during the day and conserve energy for more important activities. Exercise can help combat fatigue; a simple daily walk with a friend can help. Talk to your healthcare team for helpful tips on dealing with this side effect.
Some patients may develop a rash. Use an alcohol free moisturizer on your skin and lips; avoid moisturizers with perfumes or scents. If your skin does crack or bleed, be sure to keep the area clean to avoid infection. Be sure to notify your oncology care team of any rash that develops, as this can be a reaction. They can give you more tips on caring for your skin.
This medication can affect the normal levels of electrolytes (phosphate, etc.) in your body. Your levels will be monitored using blood tests. If your levels become too low, your care team may prescribe specific electrolytes to be given by IV or taken by mouth. Do not take any supplements without first consulting with your care team.
This medication can cause higher than normal levels of uric acid in your body. Your care team will monitor for this and other things with blood work.
Exposure of an unborn child to this medication could cause birth defects, so you should not become pregnant while on this medication. Effective birth control is necessary during treatment and for at least 1 month after the last dose. Even if your menstrual cycle stops or you believe you are not producing sperm, you could still be fertile and conceive. You should not breastfeed during treatment and for at least 1 month after the last dose.
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.
Information Provided By: www.oncolink.org | © 2025 Trustees of The University of Pennsylvania